Boston Scientific Q4 rev $3.24B (+3.7% reported); adj. EPS $0.45 flat YoY; guides FY23 adj. EPS $1.86-$1.93

BOSTON SCIENTIFIC CORP

2022-FY EPS reported $0.45 revenue$12,682,000,000

Q4 net sales $3.242B, up 3.7% reported, 7.1% organic; GAAP EPS $0.09 ($126M net income), adj. EPS $0.45.
FY22 net sales $12.682B (+6.7% reported); GAAP EPS $0.45; adj. EPS $1.71 vs $1.63 prior year.
FY23 guidance: reported sales growth 5-7%, organic 6-8%; adj. EPS $1.86-$1.93; Q1 adj. EPS $0.42-$0.44.
Cardiovascular segment Q4 sales +6.4% reported; MedSurg +4.4% reported; US sales +10.5%.
Agreed to acquire Apollo Endosurgery and majority stake in Acotec Scientific; AGENT DCB approved in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.